Zilebesiran Program Lead At Alnylam News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 7, 2024

United kingdomUnited statesChristine regan lindenboomJosh brodskyAkshay desaiSimon foxAlnylam pharmaceuticalsHealth promotion seriesZilebesiran program lead at alnylamWorld health organizationJournal of the american college cardiologySecurities exchangeAmerican college of cardiologyExchange commissionAlnylam pharmaceuticals nasdaqHeart failure program

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

– Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Placebo-Adjusted Reduction of 24-Hour Mean Systolic Blood Pressure at Three Months of Treatment – – Study Met Key Secondary.

United statesUnited kingdomGeorgel bakrisSimon foxUniversity of chicago medicineAlnylam pharmaceuticals nasdaqAlnylam pharmaceuticalsAlnylam pharmaceuticals incZilebesiran program lead at alnylamHealth promotion seriesAmerican heart association scientific sessionsWorld health organizationAmerican heart association comprehensive hypertension centerSecurities exchangeExchange commissionAmerican heart association

Alnylam Pharma (ALNY) Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran

Alnylam Pharma (ALNY) Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomGeorgel bakrisSimon foxJosh brodskyChristine regan lindenboomHealth promotion seriesAlnylam pharmaceuticals nasdaqJournal of the american college cardiologyAlnylam pharmaceuticalsZilebesiran program lead at alnylamUniversity of chicago medicineWorld health organizationAlnylam pharmaceuticals incAmerican heart association comprehensive hypertension centerSecurities exchange

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

- Zilebesiran Met Primary Endpoint Demonstrating Greater than 15 mmHg Reduction of Systolic Blood Pressure at Three Months of Treatment Compared to Placebo at Two Highest Single Doses Evaluated - -.

United statesUnited kingdomGeorgel bakrisSimon foxJournal of the american college cardiologyExchange commissionUniversity of chicago medicineZilebesiran program lead at alnylamAlnylam pharmaceuticalsAlnylam pharmaceuticals nasdaqWorld health organizationAmerican heart association comprehensive hypertension centerSecurities exchangeHealth promotion seriesAlnylam pharmaceuticals incProfessor george

Alnylam Pharmaceuticals, Inc : Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc : Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomAkshay desaiSimon foxChristine regan lindenboomJosh brodskyAlnylam pharmaceuticalsAlnylam pharmaceuticals nasdaqJournal of the american college cardiologyZilebesiran program lead at alnylamHeart failure programSecurities exchangeAlnylam pharmaceuticals incHealth promotion seriesExchange commissionAcceptable safety profile supporting further developmentWorld health organization